However, we did not observe different frequencies of CD4 + TEM or CD8+ TEMRA cells in patients who subsequently developed hepatitis after anti-PD-1 & anti-CTLA-4 therapy (Fig. 6A), and there was no difference in the T cell subset distribution between patients which did or did not develop hepatitis according to CMV serology status (Fig. 6B). This evidence concerns the gene CTLA4 and hepatitis A virus infection.